Get the terms in writing
Start with a plain request: name the medicine and show the charges around it. Ask for the form of the drug and the reason for suggesting it. Then request the service fee, the medicine charge and any separate testing or follow-up charges.
In the September 2026 service sample, a program membership did not include the semaglutide medicine charge. The sample was small and described advertised terms, not completed purchases.
That is a reason to ask what an offer includes rather than assume. Keep an “unanswered” space on the list. A missing price can remain missing until the service gives a clear answer; there is no need to make a reassuring guess to finish the cost check.
Ask about the later bill
The manufacturer offer for semaglutide (Ozempic injection), recorded in September 2026, limited its $199 price to the first two monthly fills for eligible new self-pay patients at specified introductory strengths. The window was published through December 31, 2026.
Put the later price next to the opening offer. Ask whether the service fee also changes. Request the commitment, renewal and cancellation terms in the same reply. Read the answer as a description of the actual offer, not as a rule that every program follows.
If advance payment is planned, ask what it purchases and what the written terms say about unused care. Ask what happens if the review does not lead to a prescription or the coverage request is declined. Keep these questions apart so a reply about one fee does not seem to answer every charge.
Ask who makes the medical decisions
In its guidance reviewed in September 2026, the FDA warned against describing a compounded drug as FDA-approved. Claims that it matches an approved drug were also misleading.
If a compounded drug is planned, ask for that description plainly. Ask which pharmacy prepares it and why that route is being planned. Put the answer beside the product name, not just beside the cheapest amount on the sheet.
Under the FDA’s April 2026 position, checked again that September, adding a vitamin could still leave semaglutide subject to limits on pharmacy-made copies. The FDA looked for a written judgment by the person writing the prescription that the change made a meaningful difference for a named person.
The next question is about the actual planned care, not how to claim an exception. Ask for a plain account of why this route is being suggested for the care at hand.
Leave with a follow-up contact route
Ask how to raise a medical concern, how billing questions are handled and what later contact is included in the fee. Ask who reviews outside results and what happens if care needs to move in person. Keep the replies with the price terms.
The note box below is for a short question list. Saving keeps its text in this browser; it does not send a message to a service. Anyone using this browser may be able to read saved text. Leave private health details out of this box and use the care service’s own process for sharing medical records.
Keep a question list
This box saves only when Save notes is selected. Keep a separate copy if these notes matter to you.
To save here, the browser needs JavaScript, the feature that lets these buttons work. You can still copy your text elsewhere.